Traders Buy Pfizer Inc. (PFE) on Weakness
Investors purchased shares of Pfizer Inc. (NYSE:PFE) on weakness during trading hours on Friday. $385.96 million flowed into the stock on the tick-up and $51.88 million flowed out of the stock on the tick-down, for a money net flow of $334.08 million into the stock. Of all companies tracked, Pfizer had the 12th highest net in-flow for the day. Pfizer traded down ($0.20) for the day and closed at $33.94
A number of equities research analysts have commented on the stock. Jefferies Group decreased their price objective on shares of Pfizer from $40.00 to $39.00 and set a “buy” rating on the stock in a report on Tuesday, September 13th. Argus reissued a “buy” rating and set a $39.00 price objective on shares of Pfizer in a report on Sunday, August 28th. Bank of America Corp. set a $40.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, August 22nd. Piper Jaffray Cos. set a $54.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, August 23rd. Finally, BMO Capital Markets reissued an “outperform” rating and set a $40.00 price objective on shares of Pfizer in a report on Tuesday, August 23rd. Ten research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Pfizer has a consensus rating of “Buy” and an average price target of $38.78.
The firm’s 50-day moving average is $35.23 and its 200-day moving average is $33.72. The stock has a market capitalization of $205.87 billion, a price-to-earnings ratio of 30.09 and a beta of 0.87.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.02. The firm had revenue of $13.10 billion for the quarter, compared to analysts’ expectations of $13.01 billion. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.56 EPS. Equities analysts anticipate that Pfizer Inc. will post $2.46 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 1st. Shareholders of record on Friday, August 5th were issued a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.54%. The ex-dividend date of this dividend was Wednesday, August 3rd. Pfizer’s payout ratio is 95.24%.
Institutional investors have recently bought and sold shares of the company. Nelson Roberts Investment Advisors LLC boosted its position in Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 189 shares during the last quarter. Stelac Advisory Services LLC acquired a new position in Pfizer during the second quarter worth about $110,000. Tuttle Tactical Management LLC acquired a new position in Pfizer during the second quarter worth about $117,000. Catamount Wealth Management boosted its position in Pfizer by 14.2% in the first quarter. Catamount Wealth Management now owns 4,395 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 545 shares during the last quarter. Finally, Delphi Private Advisors LLC boosted its position in Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 47 shares during the last quarter. Hedge funds and other institutional investors own 69.66% of the company’s stock.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.